The process of managing medications in patients with borderline personality disorder

Journal of Psychiatric Practice

Volumn 17, Issue 5, 2011, Pages 311-319

  Silk, Kenneth R ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

borderline personality disorder; collaborative treatment; medication management; patient therapist interaction; polypharmacy; psychopharmacology

Indexed keywords

BENZODIAZEPINE DERIVATIVE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; ARTICLE; BIPOLAR II DISORDER; BORDERLINE STATE; CLINICAL FEATURE; COMORBIDITY; DEPRESSION; HUMAN; MAJOR DEPRESSION; MENTAL INSTABILITY; MENTAL PATIENT; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WITHDRAWAL SYNDROME;

BORDERLINE PERSONALITY DISORDER; HUMANS; MEDICATION ADHERENCE; PHYSICIAN-PATIENT RELATIONS; POLYPHARMACY; PSYCHOTROPIC DRUGS;

EID: 80053074425     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000405361.88257.4a     Document Type: Article

References (47)

1. Zanarini MC, Frankenburg FR, Hennen J, et al. The McLean Study of Adult Development (MSAD) Overview and implications of the first six years of prospective follow-up. J Pers Disord 2005;19 505-23. (Pubitemid 41618524)
2. Skodol AE, Gunderson JG, Shea MT, et al. The Collaborative Longitudinal Personality Disorders Study (CLPS) Overview and implications. J Pers Disord 2005;19 487-504 (Pubitemid 41618523)
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC American Psychiatric Association; 2000.
4. Paris J, Brown R, Nowlis D. Long-term follow-up of borderline patients in a general hospital. Compr Psychiatry 1987;28 530-5. (Pubitemid 18018780)
5. Plakun EM, Burkhardt PE, Muller JP. 14-year follow-up of borderline and schizotypal personality disorders. Compr Psychiatry 1985;26 448-55. (Pubitemid 15006062)
6. McGlashan T. The Chestnut Lodge follow-up study, II Long-term outcome of borderline personalities. Arch Gen Psychiatry 1984 41 586-601. (Pubitemid 14111387)
7. Linehan MM, Armstrong H, Suarez A, et al. Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry 1991;48 1060-4.
8. Davidson K, Norrie J, Tyrer P, et al. The effectiveness of cognitive behavior therapy for borderline personality disorder Results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. J Pers Disord 2006;20 450-65. (Pubitemid 44580879)
9. Bateman A, Fonagy P. The effectiveness of partial hospi-talization in the treatment of borderline personality disor-der-A randomized controlled trial. Am J Psychiatry 1999;156 1563-9. (Pubitemid 29459988)
10. Clarkin JF, Levy KN, Lenzenweger MF, et al. Evaluating three treatments for borderline personality disorder A multiwave study. Am J Psychiatry 2007;164 922-8. (Pubitemid 46972908)
11. Giesen-Bloo J, van Dyck R, Spinhoven P, et al. Outpatient psychotherapy for borderline personality disorder. Randomized trial of schema-focused therapy vs transference-focused psychotherapy. Arch Gen Psychiatry 2006;63 649-58. (Pubitemid 43848296)
12. Blum N, St. John D, Pfohl B, et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder A randomized controlled trial and 1-year follow-up. Am J Psychiatry 2008;165 468-78. (Pubitemid 351694290)
13. Zanarini MC, Frankenburg FR, Hennen J, et al. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry 2004;65 28-36.
14. Bender DS, Dolan RT, Skodol AE, et al. Treatment utilization by patients with personality disorders. Am J Psychiatry 2001;158 295-302. (Pubitemid 32116528)
15. American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry 2001;158 1-52.
16. National Institute for Health and Clinical Excellence (NICE). Borderline personality disorder, treatment and management. London The British Psychological Society and The Royal College of Psychiatrists; 2009 (available at www.nice.org.uk/CG78, accessed June 25, 2011).
17. Stoffers J, Völlm BA, Rücker G, et al. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 2010 6 CD005653.
18. Saunders EFH, Silk KR. Personality trait dimensions and the pharmacologic treatment of borderline personality disorder. J Clin Psychopharmacol; 2009 29 461-7.
19. Siever LJ, Davis KL. A psychobiological perspective on the personality disorders. Am J Psychiatry 1991;148 1647-58.
20. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6 278-96.
21. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134 382 9.
22. Derogatis LR. SCL-90-R, Brief Symptom Inventory, and matching clinical rating scales. In Maruish M, ed. The use of psychological tests for treatment planning and outcome assessment. New York; Erlbaum 1994 217-48.
23. Zanarini MC, Stanley B, Black D W, et al. Methodological considerations treatment trials for persons [with] personality disorder. Ann Clin Psychiatry 2010;22 75-83.
24. Duggan C, Huband N, Smailagic N, et al. The use of pharmacological treatments for people with personality disorder A systematic review of randomized controlled trials. Personal Ment Health 2008; 2 119-70.
25. Herpertz SC, Zanarini M, Schulz CS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry 2007;8 212-44. (Pubitemid 350018476)
26. Ingenhoven T, Lafay P, Rinne T, et al. Effectiveness of pharmacotherapy for severe personality disorders Meta-analyses of randomized controlled trials. J Clin Psychiatry 2010;71 14-25.
27. Lieb K, Völlm B, Rücker G, et al. Pharmacotherapy for borderline personality disorder Cochrane systematic review of randomised trials. Br J Psychiatry 2010;196 4-12.
28. Mercer D, Douglass AB, Links PS. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder Effective-ness for depression and anger symptoms. J Pers Disord 2010;23 156-74.
29. Cornelius JR, Soloff PH, Perel JM, et al. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry 1993;150 1843-8. (Pubitemid 23356578)
30. Zanarini MC, Frankenburg FR, DeLuca CJ, et al. The pain of being borderline Dysphoric states specific to borderline personality disorder. Harv Rev Psychiatry 1998; 6 201-7. (Pubitemid 28507381)
31. Main TF. The ailment. Br J Med Psychol 1960;33 29-31.
32. Bender DS, Skodol AE. Borderline personality as a self-other representational disturbance. J Pers Disord 2007; 21 500-17. (Pubitemid 350006879)
33. Schlesinger AB, Silk KR. Collaborative treatment. In Oldham JM, Skodol AS, Bender DS, eds. The American Psychiatric textbook of personality disorders. Washington, DC American Psychiatric Publishing; 2005 431-46.
34. Bender DS. The therapeutic alliance in the treatment of personality disorders. J Psychiatr Pract 2005;11 73-87. (Pubitemid 40471367)
35. LeQuesne ER, Hersh RG. Disclosure of a diagnosis of borderline personality disorder. J Psychiatr Pract 2004;10 170-6. (Pubitemid 38669725)
36. Zanarini MC, Frankenburg FR. A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. J Pers Disord 2008;22 284-90.
37. Perry JC. Depression in borderline personality disorder Lifetime prevalence at interview and longitudinal course of symptoms. Am J Psychiatry 1985;142 15-21. (Pubitemid 15189514)
38. Silk KR. The quality of depression in borderline personality disorder and the diagnostic process. J Pers Disord 2010;24 25-37.
39. Westen D, Moses J, Silk KR, et al. Quality of depressive experience in borderline personality disorders When depression is not just depression. J Pers Disord 1992;6 382-93 (Pubitemid 23049856)
40. Gunderson JG, Morey LC, Stout RL, et al. Major depressive disorder and borderline personality disorder revisited Longitudinal interactions. J Clin Psychiatry 2004;65 1049-56
41. Silk K, Feurino L, III. Psychopharmacology of personality disorder. In Widiger T, ed. Oxford handbook of personality disorders. New York Oxford University Press, in press.
42. Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms A randomised study. J Psychopharmacol 2008;22 330-2. (Pubitemid 351847442)
43. Weinberg I, Ronningstam E, Goldblatt MJ, et al. Common factors in empirically supported treatments of borderline personality disorder. Curr Psychiatry Rep 2011;13 60-8.
44. Bateman A, Zanarini M. Personality disorder. In Tyrer P, Silk KR, eds. Cambridge textbook of effective treatments in psychiatry. New York Cambridge University Press; 2008 659-81.
45. Zanarini MC, Frankenburg FR, Reich DB, et al. The sub-syndromal phenomenology of borderline personality disorder A 10-year follow-up study. Am J Psychiatry 2007;164 929-35 (Pubitemid 46972909)
46. Waldinger RJ, Frank AF. Transference and the vicissitudes of medication use by borderline patients. Psychiatry 1989;52 416-27. (Pubitemid 20005940)
47. Gunderson JG, Links PS. Borderline personality disorder, A clinical guide, second edition. Washington, DC American Psychiatric Publishing 2008.